no. there's no data to go on as yet. as retiredyoung said it will turn on
a) qtrly sales + it will also be on
b) sales outlook
c) sector sentiment
i have no idea how my words suggested that kind of conclusion
put it in perspective - PNV trades at close to ~3x the market cap with almost identical cash burn/stage of life cycle, identical cash on hand and quite similar global sales potential. from my research BUD should have superior marginal unit profitability - but its market is unproven.
pnv is medtech - which tends to be seen as 'safe' harbour - demand for burn graft solutions doesnt change due to global economics. thats why its held its valuation more easily imo
given that BUD probably has more upside risk than downside - but that is only true whilever market is sanguine the BUD business model will ultimately work
at current prices thats an easy call to make about where money should flow. if BUD was at 30c that risk/return tradeoff would be much harder to parse imo
